natgillin/translations-raw huggingface dataset:
For purposes of this description, the term "crop" will be used to refer to an example of a target product, and includes any plant material, whether pre-harvested (e.g. growing in a field or cut but without the desired part being yet harvested), or during and after harvesting. 
Za svrhe ovog opisa, izraz "usjev" koristit će se na način da se odnosi na neki primjer jednog ciljnog proizvoda, a obuhvaća bilo koji biljni materijal bilo da je neubran (na primjer da raste u polju ili da je rezan ali da željeni dio još nije ubran) ili tijekom i poslije žetve.
The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition being treated, recommendations of the treating physician, and the therapeutics or combination of therapeutics selected for administration. 
Točna efikasna količina za subjekt će ovisiti od veličine i zdravlja subjekta, prirode i težine stanja koje se liječi, preporuka nadležnog liječnika 1 lijekova ili kombinacije lijekova izabranih za primjenu.
Preferably the antibody selected in step (c) in the above methods inhibits the binding of a HLA-C allele molecule having a Lys residue at position 80 to a human KIR2DL1 receptor, and the binding of a HLA-C allele molecule having an Asn residue at position 80 to human KIR2DL2/3 receptors. 
HLA-c alel molekule koja ima Lys ostatak na položaju 80, za humani KIR2DLI receptor, i vezanje HLA-C alel molekule, koja ima Asn ostatak na položaju 80, za humane KIR2DL2/3 receptore.
The sides of the holder cannot be separated. 
Stranice držača se ne mogu odvojiti.
A pharmaceutical composition comprising the antibody of claim 1 or 2 and a pharmaceutically acceptable carrier or excipient. 
Farmaceutska kompozicija koja sadrži antitijelo prema patentnom zahtjevu 1 ili 2 1 farmaceutski prihvatljiv nosač ili ekscipijens.
A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 20 to 30 linked nucleosides and has a nucleobase sequence comprising the nucleobase sequence of SEQ ID NO: 440, wherein the oligonucleotide is at least 80% complementary to SEQ ID NO: 1 or 2 and wherein the conjugate group comprises: 
HR P20191664 T1 PATENTNI ZAHTJEVI Spoj koji sadrži modificirani oligonukleotid i konjugiranu skupinu, gdje modificirani oligonukleotid se sastoji od 20 do 30 vezanih nukleozida i ima nukleobaznu sekvencu SEQ ID NO: 440, gdje je oligonukleotid bar 80% komplementaran sa SEQ ID NO: 1 ili 2 i gdje konjugirana skupina obuhvaća:
a sulfonyl urea or/and a pharmaceutically acceptable salt thereof, particularly for oral administration. 
(b) sulfonil ureu ili/i njegovu farmaceutski prihvatljivu sol, naročito za oralnu primjenu.
R21 at each occurrence is independently selected from H and C1-C6 alkyl; 
R"' uvijek kada se pojavljuje je neovisno odabran od H i C;-C4, alkila;
The pharmaceutical composition according to the invention comprises a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof. 
HR P20171708 T1 PATENTNI ZAHTJEVI Farmaceutski pripravak naznačen time da je za uporabu za sprječavanje 1li liječenje boli koji sadrži: a) prvi farmakološki aktivni sastojak izabran od spoja prema kemijskoj formuli (1) i njihove fiziološki prihvatljive soli
It is preferably a rigid construction, particularly when the fluid 12 is contained in a bag 14 in the container 13 . 
On je ponajprije krute konstrukcije, posebno ako se fluid 12 nalazi u vrećici 14 u spremniku 13.
A pharmaceutical composition comprising an antibody according to claim 1, in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier, wherein the pharmaceutical composition optionally comprises other active ingredients. 
Farmaceutski pripravak koji sadrži antitijelo prema bilo kojem od patentnih zahtjeva od 1 do 3, u kombinaciji sa jednim ili više farmaceutski prihvatljivim ekscipientom, otapalom ili nosačem; naznačen time da farmaceutski pripravak sadrži po izboru sadrži druge aktivne sastojke.
The photocatalytic nanoparticles may have a primary particle size of less than 50 nm, preferably less than 30 nm, more preferably less than 20 nm, most preferably less than 10 nm. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da fotokatalitičke nanočestice imaju primarnu veličinu čestica manju od 50 nm, poželjno manju od 30 nm, poželjnije manje od 20 nm, a najpoželjnije manje od 10 nm.
This activity phosphorylates key tyrosine amino acids in target proteins, resulting in the transduction of proliferative signals across the plasma membrane of the cell. 
Ova aktivnost fosforilira ključne aminokiseline u ciljnim proteinima, što rezultira prijenosom signala za proliferaciju preko plazmine membrane stanice.
Minimum relative amount (Weight %) 
Sastojak količina (težinski %)
For water temperatures of 69 degrees Celsius or more, maintaining said water's ORP of at least 500 mV for a minimum period of 1 hour; 
za temperature vode od 70 stupnjeva Celzija ili više, održavanje navedenog ORP-a vode od najmanje 500 mV tijekom minimalnog razdoblja od 1 sata;
On the other hand, sufficient binder must be included to hold the fuel element together during manufacture and use. 
S druge strane, mora se uključiti dovoljno vezivnog sredstva za zajedničko držanje gorivog elementa za vrijeme proizvodnje i korištenja.
The filtrate is rinsed several times by re-suspending it in ethanol by manually stirring and subsequently filtrating. 
Filtrat je nekoliko puta ispran i ponovo suspendiran ručno u etanolu ručnim miješanjem a zatim je filtriran.
Analysis of Average 24-hour LISR Total Presence Scores, ITT Population 
Grafikon po danima (Day) za prosječna 24-satne vrijednosti lskaine reakcije na mjestu E
the mature type I elastase comprises an amino acid sequence with at least 85% sequence identity, at least 95% sequence identity, at least 98% sequence identity or at least 99% sequence identity, or comprises 100% sequence identity, to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:78, or SEQ ID NO:84; or 
(i) zreli tip I elastaze obuhvaća sekvencu aminokiseline sa najmanje 85% identičnosti sekvence, najmanje 95% identičnosti sekvence, najmanje 98% identičnosti sekvence ili najmanje 99% identičnosti sekvence, ili sadrži 100% identičnosti sekvence, u sekvenci aminokiseline SEK ID BR: 1, SEK ID BR: 78 ili SEK ID BR: 84: ili
To the warm solution, heptanes (800mL) were added and the solution was cooled in the refrigerator and filtered. 
Vrućoj otopini su bili dodani heptani (800 mL) i otopina je bila ohlađena u hladnjaku i filtrirana.
Preferably, Z represents a bond. 
Po mogućnosti, nje 0,amje 1.
An indolizine derivative as claimed in claim 2, wherein the group represented by the formula: 
Derivat indolizina prema zahtjevu 2, gdje skupina predstavljena formulom:
Further, some examples of food preparations are given for the illustration of the invention. 
Nadalje, za ilustraciju izuma navode se i neki primjeri priprave jela.
The compound or pharmaceutically acceptable salt for use according to claim 3, wherein the disease, health condition or disorder is selected from liver cirrhosis; liver cirrhosis associated with chronic liver disease; hepatic fibrosis, hepatic stellate cell activation, and hepatic fibrous collagen. 
Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 3, pri čemu se bolest, zdravstveno stanje ili poremećaj odabire među cirozom jetre; cirozom jetre povezanom s kroničnom bolesti jetre; hepatičnom fibrozom, aktivacijom jetrenih zvjezdanih stanica i fibroznim kolagenom jetre.
The retention times, Rt, are expressed in minutes. 
Vremena retencije, R., izražena su u minutama.
A system as claimed in claim 1, wherein the control device is implemented through a server that receives data according to a TCP/IP standard and that contains a knowledge base with all active credentials. 
Sistem kao u patentnom zahtjevu 4, gdje je kontrolni uređaj (301) implementiran kroz server koji prima podatke u skladu sa TCP/IP standardom i koji sadrži bazu znanja (315) sa svim aktivnim odobrenjima.
U.S. Pat. No. 4,018,830 and U.S. Pat. No. 4,055,665 discloses “phenylthioaralkylamines” and “2-phenylthiobenzylamines” represented structurally as “Ar1—S—Ar2 in which Ar1 is a phenylalkyl amine substituent and Ar2 is a substituted or unsubstituted homocyclic or heterocyclic ring of from 5-6 atoms, such as an aromatic ring, a heteroaromatic ring”. 
US 4,018,830 i US 4,055,665 opisuju "feniltioaralalkilamine" i "2-feniltiobenzilamine" koji su strukturalno predstavljeni kao "Ar;,-S-Ar»" u kojem je Ar, fenilakil amin supstituent, a Ar, je supstituirani ili nesupstituirani homociklični ili heterociklični prsten 5-6 atoma, kao što je to aromatični prsten, heteroaromatični prsten".
The method of treating plants according to the present invention is characterized in that in the treatment of leaves from 0.1 to 10 000 g active compound combination or fungicidal composition per ha and in the treatment of seed from 2 to 200 g active compound combination or fungicidal composition per 100 kg of seed are employed. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 5 do 7, naznačen time što se za tretman lišća koristi 0.1 do 10 000 g kombinacije aktivnog spoja/ha i za tretman sjemena se koristi od 2 do 200 g kombinacije aktivnog spoja po 100 kg sjemena.
The tornado yoyo according to claim 1, wherein a protruding axle (33) configured to be held by a player or be plucked by a yo-yo string protrudes outwards from the middle of an outer surface of each rotating cap (3). 
Tornado yo-yo u skladu s patentnim zahtjevom 1, naznačen time, da izbočena osovina (33) konfigurirana tako da je drži igrač ili da je izvučena yo-yo kabelom, strši prema van od sredine vanjske površine svake rotirajuće kapice (3).
wherein the sealing member is pressed against the first enclosing member to form a flow resistance which prevents the fluid from bypassing the ingredients in the capsule and which is effective to enable pressure in the capsule to rise sufficiently until the opening of the outlet face. 
- pri čemu je element za brtvljenje (8) potisnut na pripadajući element za obuhvaćanje čahure da bi se stvorio otpor za protok koji djeluje tako da se može dovoljno povećati tlak u čahuri, (1) sve dok se ne otvori izlazna ploha,
Pressure tank according to claim 1 or 2, characterized in that the flow connector pipes (15 and 15a) are welded into inner bottom (4) and/or upper divider (6) this way, that part of the flow connector pipe (15 and 15a) with walls in the range of 0,3 up to 1,7 of thickness of element walls, where it is welded, is connected with tank elements by a weld seam of a length not less than ¼ of the outer circumference of the connector pipe, where it has its smallest diameter. 
Tlačni spremnik u skladu s patentnim zahtjevom 1 ili 2, naznačen time što su protočne spojne cijevi (15 i 15a) zavarene u donje dno (4) i/ili gornji separator (6) s te strane, što je dio protočne spojne cijevi (15 i 15a) sa stijenkama u rasponu od 0,3 do 1,7 debljine elementa stijenke, gdje je zavaren, povezan s elementima spremnika varom dugim najmanje 1/4 vanjskog oboda spojne cijevi, gdje joj je promjer najmanji.
Sucrose is currently preferred. 
Trenutno je poželjna saharoza.
A 7-(Morpholinyl)-2-(N -piperazinyl)methyl thieno[2,3-c]pyridine compound of Formula-I or a pharmaceutically acceptable salt thereof, wherein: 
Spoj 7-(morfolinil)-2-(N-piperazinil) metil tieno[2, 3-c]piridina formule I ili njegova farmaceutski prihvatljiva sol, naznačeno time, što:
Figure 3 shows part of a second sampler according to the invention in a first position; 
Slika 3 prikazuje dio druge naprave za uzimanje uzorka, koja je u skladu s ovim, izumom u prvom položaju;
The formulation of claim 1, wherein deferiprone is present in an amount of about 50 grams to about 200 grams per liter of the formulation. 
Formulacija zahtjeva 1, gdje je deferipron prisutan u količini od oko 50 grama do oko 200 grama po litri formulacije.
an Ab, or an antigen binding fragment thereof, wherein said Ab binds to human Axl and is selected from the group consisting of: 
Ab, ili njegov fragment vezan na antigen, koji se može vezati za humani protein Axl odabran od:
A plant according to claim 1, wherein the closed loop includes a pressure controlling mechanism by which the pressure through the second heat exchanger and NG/coolant heat exchanger is maintained above the boiling pressure by seawater at a temperature range of 5-35° C. 
Postrojenje prema zahtjevu 1, naznačeno time što je medij za zagrijavanje morska voda, a tlak kroz izmjenjivač topline (D) i izmjenjivač topline prirodni plin/frashladno sredstvo (C) se održava iznad tlaka ključanja na temperaturi morske vode.
The wind turbine according to claim 1, wherein the fork is fastened to a lower base portion of the nacelle. 
Vjetroturbina (1) prema patentnim zahtjevima 11 7, pri čemu je navedena vilica (6) pričvršćena na navedeni donji deo (20) baze.
First of all, the data area of a data portion on a data sheet, in which the data included on the data sheet is recorded, should be of such a structure that a counterfeiter is unable to disassemble it. 
Prije svega, prostor za podatke predjela za podatke na listu za podatke, na kojemu su zapisani podaci koji su sadržani na listu za podatke, treba biti tako izrađen da ga krivotvoritelj ne može rastaviti.
This reaction is carried out at room temperature, preferably in acetonitrile/water (2:1), in the presence of sodium hydrogen carbonate (NaHCO3). 
Ta reakcija je izvedena pri sobnoj temperaturi, preferirano u acetonitril/vodi (2:1) u prisutnosti natrijeva hidrogenkarbonata (NaHCO;).
associating one or more ("yyy") tags to said internet addresses or to said added internet addresses; 
povezivanje jedne ili više oznaka (,,yyy'‘) s navedenim internetskim adresama ili s navedenim dodanim internetskim adresama;
a capsule punching mechanism (4) which punches the capsule (3) whereby enabling its content to be poured into the cooking chamber (2), 
- < mehanizam (4) za bušenje kapsule koji buši kapsulu (3) da se omogući da se njezin sadržaj izlije u komoru za kuhanje (2),
A compound of formula (XI) an N-oxide, addition salt or stereochemically isomeric form thereof. 
Spoj s formulom (XI) [image] N-oksid, adicijska sol ili njegov stereokemijski izomerni oblik.
Flavoring agents also may be incorporated into the article to flavor the aerosol delivered to the user. 
Također se u proizvod mogu inkorporirati mirisna sredstva za davanje mirisa aerosolu koji se provodi prije korisniku.
The method of claim 7, wherein the target cell is a human tumor cell and the agent binds an epitope of the human tumor cell. 
(d) humana tumorska stanica, a terapijsko antitijelo se specifično vezuje za epitop humane tumorske stanice.
introducing at least one inlet (11) for injection material, which inlet ends at a first side of the assembly (3), 
- < uvođenje barem jednog ulaza (11) za injciranje materijala, taj ulaz završava na prvoj strani sklopa (3),
a coordinating ether solvent that has low miscibility with water; or an ether solvent that has low miscibility with water and a coordinating co-solvent, provided that the coordinating co-solvent constitutes no more than 20% v/v of the reaction mixture; 
(1) koordinacijsko etersko otapalo koji ima nisku mješavost sa vodom; ili (ii) etersko otapalo koje ima nisku mješavost sa vodom i koordinacijsko ko-otapalo, uz uvjet da koordinacijsko 10
The cushion as claimed in claim 1 or 2 wherein the envelope (12) provides a sealed chamber for the resilient core (17). 
Jastuk prema patentnim zahtjevima 1 ili 2 pri čemu ovojnica (12) omogućuje zatvorenu komoru za elastičnu jezgru
In another aspect, the present invention provides an FeLV ENV polynucleotide having a nucleotide sequence as set forth in SEQ ID NO: 1, 3, or 5, or a variant thereof. 
Sastav prema zahtjevu 1 ili zahtjevu 2, naznačen time, da polinukleotid koji kodira ENV polipeptid za FeLV, ima najmanje 80% identiteta sekvence od sekvence prikazane u SEQ ID NO: 1, 3 ili 5.
The composition according to any one of the preceding claims, comprising at least one hydrophilic gelling agent selected from the group consisting of glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, carbopol® polymers, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin, and gelatin. 
Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, koja dalje sadrži najmanje jedan hidrofilni agens za geliranje odabran od glukoze, modificiranog škroba, metil celuloze, karboksimetil celuloze, propil celuloze, hidroksipropil celuloze, karbopol (RTM) polimera, alginske kiseline, natrij alginata, kalij alginata, amonij alginata, kalcij alginata, agara, karagenana, karuba gume, pektina, i želatina.
Preparation of ultra high molecular weight polyethylene 
KATALIZATORI ZA PRIPRAVU POLIETILENA ULTRA VISOKE MOLEKULSKE MASE
Also provided is a product comprising (a) a corticosteroid and (b) an M3 antagonist of the invention as a combined preparation for simultaneous, separate or sequential use in the treatment of a human or animal patient. 
Također je omogućen proizvod koji sadrži (a) B2-agonist 1 (b) M3 antagonist sukladno predmetnom izumu u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u liječenju bolesnih ljudi ili životinja.
is heteroaryl optionally substituted with one substituent selected from F; heteroaryl is selected from the group consisting of pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, isoxazolyl, pyrazolyl and triazolyl; and 
R' je heteroaril po izboru supstituiran jednim supstituentom izabranim između F; heteroaril se izabire iz skupine koja obuhvaća piridinil, pirazinil, piridazinil, pirimidinil, izoksazolil, pirazolil i triazolil; i
The remainder of the wall element 2 is smaller. 
Ostatak zidnog elementa 2 je manji.
Inside the second seat 21 there is positionable a further component for the above-mentioned adjustment means of the axial position with respect to the sole 2, such component being constituted by a second screw 24 having a first cylinder or shank 25, axially counter-toothed to the toothing 22 and engageable therewith; the second screw 24 is rotatably positionable at the second hole 11 and the third hole 12. 
Unutar drugog dosjeda 21 može se smjestiti daljnja komponenta za gore spomenuto sredstvo za podešavanje aksijalnog položaja u odnosu na potplat 2, pri čemu tu komponentu tvori drugi vijak 24 koji ima prvi cilindar ili ravni dio 25,1 aksijalno je suprotno nazubljen u odnosu na nazubljenje 22, pa se može s njim zakvačiti, dok drugi vijak 24 se može okretno namjestiti na drugu rupicu 11 i treću rupicu 12.
According to a further preferred embodiment, the EPA and DHA ethyl esters assay is at least 80% by weight, the EPA ethyl ester assay being at least 40% by weight and the DHA ethyl ester assay being at least 34% by weight; the total w-3 acids ethyl esters assay being at least 90% by weight. 
Prema daljnjem poželjnom ostvarenju, udio EPA i DHA Â«til estera je najmanje 80 % po masi, udio EPA etil estera najmanje 40 % po masi i udio DHA etil estera najmanje 34 % po masi; ukupni udio etil estera 0-3 kiselina je najmanje 90 % po masi.
The single immunoglobulin variable domain antibody of claim 1 or 2, wherein the antibody is linked to a polyethylene glycol (PEG) by a PEGylation reaction. The single immunoglobulin variable domain antibody of claim 3, wherein the PEG is linear. 
Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu iz zahtjeva 2, naznačeno time, što formatiranje podrazumijeva vezivanje antitijela koje sadrži jednu imunoglobulinsku varijabilnu domenu za polietilen-glikol (PEG), reakcijom PEGilacije.
The method according to any of the preceding claims, wherein a filter belt covers at least a part of the surface of the pore roller, in particular a filter belt surrounding the surface of the pore roller. 
Postupak prema jednom od prethodno navedenih zahtjeva, naznačen time da filtarska traka pokriva barem dio površine valjka s porama, osobito filtarska traka koja obuhvaća površinu valjka s porama.
an antibiotically active compound of the following formula I: in which 
PATENTNI ZAHTJEVI 1. Spoj sljedeće formule Ia:
Use of compounds according to any of Claims 1 to 3 in the preparation of a medicament for the treatment of psoriasis, bullous pemphigoid, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, glomerulonephritis and in the prevention and the treatment of injury caused by ischemia and reperfusion. 
Uporaba spojeva prema bilo kojem zahtjevu 1 do 3, naznačena time, da se oni koriste u pripravi lijekova za liječenje psorijaze, buloznog pemfigoida, rematoidnog artritisa, ulcerativnog kolitisa, akutnog respiratornog distres sindroma, idiopatske fibroze, cistične fibroze, kronične opstruktivne plučne bolesti, glomerulonefritisa i u prevenciji i liječenju oštečenja izazvanih ishemijom i reperfuzijom.
orientation and arrangement means (51, 52) of said glass fibers (5A, 5B) to orient them according to said axial direction X and to arrange them so as to configure a substantially axially extending profile (15); 
sredstva za orijentaciju i razmještaj (51,52) spomenutih staklenih vlakana (5A,5B) da bi se ona orijentirala u skladu sa spomenutim osnim pravcem X, a da njihov razmještaj da konfiguraciju značajno osno istegnutog profila (15);
The system as claimed in claim 1 wherein each electro-discharge nozzle further comprises a reflector disposed at the inlet, the reflector being movable to act as a check valve to admit water into the discharge chamber and to reflect a shockwave generated by the discharge. 
Sustav prema zahtjevu 1, pri čemu elektroerozijska mlaznica (2b) dalje obuhvaća reflektor smješten na izlazu, koji se može micati i tako ponašati kao kontrolni ventil u svrhu primitka vode u izbojnu komoru i odbijanja udarnog vala nastalog pomoću izboja (pražnjenja).
The computer program product of claim 1, wherein the method further comprises presenting an interruption to an operating system, the interruption based on the request for interruption. 
Postupak sukladno Zahtjevu 1, postupak nadalje obuhvaća prezentiranje prekida na operacijski sustav, prekid osjetljiv na zahtjev za prekid.
The vinification tank and the device according to any one of claims 1 to 4, wherein said nozzles (2) are mounted in equally spaced relationship. 
Viifikacijski spremnik 1 uređaj prema bilo kojem od patentnih zahtjeva 1 do 4, gdje su spomenute mlaznice (2) montirane u jednakim udaljenostima jedna od druge.
Pharmaceutical composition, combination product or kit according to any one of claims 1 to 7, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of ATORVASTATIN, SIMVASTATIN, PRAVASTATIN, ROSUVASTATIN and the pharmaceutically acceptable salts of these compounds. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1, 4, 5, 6, 7 ili 8, naznačen time, da je upalna plućna bolest odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
The apparatus according to claim 2, wherein the ice remover is configured to move the ice column along the first elongated element in steps corresponding to a dimension of an ice cube. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što je odstranjivač leda (202) podešen za pomicanje stupca leda (201) duž prvog izduljenog elementa (1) u koracima koji odgovaraju veličini kocke od leda (203).